Who is most at risk for meningococcal disease in Australia?

Infants under 12 months and adolescents aged 15 to 20 are the two highest-risk groups nationally, and in South Australia in particular during 2026. Others at elevated risk include people without a functional spleen, those on complement-inhibiting therapy such as eculizumab, and close household contacts of a confirmed case. During a high-incidence year the community risk profile is broader.

Is the MenB vaccine free in South Australia?

In SA, the MenB vaccine (Bexsero) is funded on the National Immunisation Program for infants at 2, 4 and 12 months of age. A school-based program also funds it for Year 10 students. Outside these cohorts the vaccine is available privately on prescription but is not federally funded. A GP can check vaccination status via the Australian Immunisation Register.

What are the early warning signs of meningococcal disease?

Early signs include sudden high fever, severe headache, neck stiffness, sensitivity to light, and vomiting — a pattern that overlaps with influenza and other viral illnesses. A non-blanching rash (small red or purple spots that do not turn white under pressure) signals bloodstream spread and is a late emergency sign. Disease can progress to death within 24 hours of symptom onset even without the rash appearing early. Anyone with sudden fever, severe headache and neck stiffness should seek emergency assessment promptly.

SA meningococcal surge: 22nd case in 2026, half of eligible unvaccinated

A young adult is on life support at an Adelaide hospital this Halloween. It is South Australia’s 22nd meningococcal disease case of 2026. At the same point in 2025, SA had recorded 13 cases.

That number — 22 versus 13 — is the thread this post pulls on.

What happened and what the case count means

SA Health confirmed the case on 31 October. Seven close contacts of the patient have been offered clearance antibiotics to prevent onward transmission; SA Health describes the risk to the broader community as low. The case is caused by meningococcal B, which accounts for the majority of invasive meningococcal disease in Australia.

The 22nd case matters not just for the individual involved — it marks a year that has run nearly 70 per cent above the equivalent point in 2025. The Australian Immunisation Handbook documents meningococcal disease’s fatality rate at up to 10 per cent even with rapid treatment. The patients who die are often young and otherwise healthy, and the trajectory from early symptoms to ICU can be measured in hours.

Speaking after the case was confirmed, SA Health Minister Blair Boyer flagged the vaccination coverage gap directly: roughly half of eligible South Australians are vaccinated for MenB. That figure, from a government minister in the immediate context of an active case, is worth sitting with.

Chief Public Health Officer Nicola Spurrier named two groups at highest risk: infants and children under five, and 15-to-20-year-olds. The funded schedule targets both — but only if families and young people take it up.

Both-and: vaccine success and an unfinished job

Meningococcal vaccination in Australia is genuinely a success story, and also one with a meaningful coverage deficit.

On the success side: the infant schedule has been effective. National meningococcal case rates fell substantially after the introduction of the MenACWY vaccine into the school program. SA’s Year 10 school program for MenB extends targeted coverage into the adolescent peak-risk window. A 2026 analysis explored how broadening MenB coverage beyond current funded cohorts could reduce the burden in the 15-to-20 age bracket, where funded access currently depends on being enrolled in Year 10 — meaning a 17-year-old who left school early, or a 21-year-old university student, has no publicly funded pathway.

On the deficit side: MenB remains outside the federal National Immunisation Program for most adolescents and adults beyond the targeted infant and Year 10 cohorts. A 22-year-old student, a 45-year-old who missed the school program, or anyone outside the explicitly funded groups pays out-of-pocket. The argument that individual risk is “low” for any single person is technically accurate — it is also the framework that produces 50 per cent coverage in a year with 22 cases.

SA Chief Public Health Officer Nicola Spurrier’s framing

Professor Spurrier pointed to the speed of meningococcal disease as the central clinical and public health challenge. It moves faster than most bacterial infections seen in general practice: a patient who presents with what looks like early viral illness in the morning can be in septic shock by evening. This is why the threshold to act on a suspicious symptom cluster is lower than for a routine febrile illness, and why waiting for the textbook non-blanching rash before seeking care carries risk — it is often a late sign, not an early one.

The implication for patients and carers is concrete: if the symptom picture includes severe headache, neck stiffness and fever together — not just one of them — emergency assessment is warranted. Not a phone triage. An emergency presentation.

2 cents: what this means this week

Three groups of people should be thinking about this case:

Parents of infants in SA. The MenB schedule is free from six weeks. If your infant’s vaccinations are not current, a conversation with a GP this week is straightforward.

Parents of teenagers or young adults. The Year 10 program provides a funded pathway, but it depends on school attendance and parental awareness. Young people who have left school in the past several years may not have gone through it. The vaccine is available privately; the conversation with a GP about whether to pursue it is low-barrier.

Anyone with symptoms suggesting meningococcal disease. Sudden-onset fever, severe headache, neck stiffness, and light sensitivity in combination is a pattern that justifies emergency assessment — not a wait-and-watch approach. The 2026 case count in SA is the backdrop.

The community risk around this specific case is being actively managed by SA Health. The broader signal — 22 cases in a year where 13 was the prior-year benchmark — is worth knowing about.

Verdict: yes — worth knowing about.